Takeda's Alunbrig (brigatinib) Receives the US FDA's Priority Review to Treat ALK + Metastatic Non-Small Cell Lung Cancer
Shots:
- The US FDA has granted PR to Takeda’s sNDA for the expanded use of Alunbrig (brigatinib) as 1L treatment for patients with ALK+ metastatic NSCLC detected by FDA-approved test
- The sNDA is based on P-III ALTA-1L study assessing the Alunbrig (180mg qd with 7days preparatory phase to 90mg qd) vs crizotinib (bid) in 275 patients with LA/m-NSCLC- prior not treated with ALK inhibitor. The study resulted in meeting its 1EPs i.e- superiority in PFS
- Alunbrig is a news generation ITK inhibitor targeting genetic alterations in ALK with its anticipated PDUFA date as Jun 23- 2020
Click here to read full press release/ article
Ref: Business wire | Image: Takeda
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com